Skip to main content
logo
Immutep Limited (ASX:IMM)
Australia flag Australia · Delayed Price · Currency is AUD
0.0460
+0.0020 (4.55%)
Sep 11, 2026, 11:02 AM AEST

Immutep Revenue

In the fiscal year ending June 30, 2026, Immutep had annual revenue of 14.60M AUD with 24,344.44% growth. Immutep had revenue of 10.50M in the half year ending June 30, 2026, with 34,682.21% growth.

Revenue
14.60M
Revenue Growth
+24,344.44%
P/S Ratio
3.25
Revenue / Employee
643.04K
Employees
31
Market Cap
64.84M

Revenue Chart

Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Jun 30, 202614.60M14.54M24,344.44%
Jun 30, 202559.71K-59.38K-49.86%
Jun 30, 2024119.09K-72.63K-37.88%
Jun 30, 2023191.72K-62.67K-24.63%
Jun 30, 2022254.39K-58.45K-18.68%
Jun 30, 2021312.84K-7.45M-95.97%
Jun 30, 20207.77M6.47M499.78%
Jun 30, 20191.29M-2.34M-64.42%
Jun 30, 20183.64M2.84M354.63%
Jun 30, 2017800.46K625.41K357.27%
Jun 30, 2016175.05K--
Jun 30, 2015---
Jun 30, 2014---
Jun 30, 2013---
Jun 30, 2012---
Jun 30, 2011---
Jun 30, 2010---
Jun 30, 2009---
Jun 30, 2008---
Jun 30, 2007---
Jun 30, 2006---
Jun 30, 2005---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Botanix Pharmaceuticals33.80M
Neurizon Therapeutics17.59M
Radiopharm Theranostics13.50M
Recce Pharmaceuticals9.47M
Amplia Therapeutics4.79M
Alterity Therapeutics3.61M
Arovella Therapeutics3.50M
Prescient Therapeutics3.45M
Revenue Rankings

Immutep News

More News